The Alexander Project, initiated in 1992 as an international, multicentre, longitudinal surveillance study of antimicrobial susceptibility among common respiratory pathogens, has been pivotal in defining the role of global surveillance. At the time, there were few studies in which data were collected in a way that allowed meaningful comparisons to be made between studies, locations or over time. The project instituted the use of a central laboratory and standardized methods for the collection of isolates and determination of susceptibility, and this was continued with the addition of two further reference laboratories. Data from the study have provided a resource for measuring trends in the susceptibility patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis at country, regional and global levels. Determination and publication of quantitative MICs enabled detailed assessment of changes in susceptibility distributions and assessment of microbiological and potential clinical susceptibility using different breakpoints, including those based on pharmacokinetic/pharmacodynamic parameters. Comparisons of antimicrobial usage patterns and resistance prevalences over time allowed hypotheses to be examined with respect to the role of quantity and type of antimicrobial use in the selection and spread of resistance. The resulting collection of isolates has provided a valuable resource for molecular studies into the evolution of resistance over time and location; a substantial proportion of this collection is now in the public domain. This paper reviews the 10 years of the Alexander Project and the benefits it has brought to an understanding of the evolution of antibacterial resistance in community respiratory bacteria.
History of the Alexander Project-rationale and design
The Alexander Project, named after Alexander the Great who it is believed died of a respiratory tract infection, was initiated in 1992 as an international, multicentre survey of antimicrobial resistance. It was designed to provide high-quality data on the prevalence of antimicrobial resistance in pathogens isolated from adult patients with community-acquired respiratory tract infections. The project has focused for a decade on the three most common bacterial respiratory pathogens: Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
At the time the study was started, few studies were conducted in a way that allowed comparison of antimicrobial resistance trends between centres or over time. Existing multicentre studies were limited to specific individual countries or geographic regions, predominantly in Europe or the USA, and it was difficult to establish a picture of how resistance was developing and spreading globally. Furthermore, differences between centres in the use of quantitative versus qualitative data analysis and variations in procedures and interpretative criteria made it difficult to assess the quality of data presented or to compare results between studies. 1 The Alexander Project was the first multicentre, international, longitudinal study of community-acquired respiratory tract infection with isolates tested against a wide range of antimicrobials using standardized testing methods in a central laboratory. 1 The use of consistent methods within a single laboratory (GR Micro, London, UK) at the inception of the project strengthened the reliability of information regarding regional differences in the prevalence of antimicrobial resistance, addressing the problem of inconsistent or non-comparable data sets. From 1998 onwards, the use of two additional US-based testing laboratories (Hersheywhile stringent cross-validation and quality control minimized the inconsistency of results between the three laboratories. Specifically, quality-control testing had three components each year (starting in 1998 and ending in 2001) . First, all lots of plates were tested against a reference panel of 50 S. pneumoniae and 50 H. influenzae isolates. Second, the three testing laboratories also tested the same set of quality-control strains, prior to starting any study testing and third, periodically during the study, the proficiency of the laboratories was assessed by having them each test a subset of 20 isolates from the quality-control isolate panel. The MICs had to be within -1 dilution (compared with the standard frozen reference result) for the drug-organism combinations. MICs outside this range were rare. Thus, the project has been an invaluable source of reliable data for the investigation of changes in antimicrobial resistance from year to year.
Methods of the Alexander Project
The Alexander Project initially collected isolates from 10 centres in five European countries, and five centres in the United States (Table 1) . 1 Each centre collected a maximum of 400 isolates of any of six respiratory pathogens: H. influenzae, Haemophilus parainfluenzae, S. pneumoniae, M. catarrhalis, Staphylococcus aureus and Klebsiella pneumoniae.
1,2 Isolates were collected from adult patients diagnosed with community-acquired respiratory tract infection, and were included from hospitalized patients only if isolates were cultured from clinical material collected during the first 48 h of the hospital stay. 2 No standard sample processing procedure was imposed on the participating centres, as existing quality-control assessment of samples and cultures was audited and considered adequate. 1 The results of in vitro testing were not recorded separately for samples collected from physicians' clinics, hospital outpatient departments and hospitalized patients meeting the above criteria. Collection of H. parainfluenzae and K. pneumoniae ceased in 1994, 2 and S. aureus was not collected after 1997, to allow the project to focus on the most clinically relevant organisms, S. pneumoniae, H. influenzae and M. catarrhalis.
Methods of transportation and storage were identical for isolates from all centres. 1, 2 For quality-control purposes, all isolates were re-identified at the regional central laboratory prior to susceptibility testing. 1, 2 The transport system, using heavily inoculated swabs maintained in Amies transport medium (Bibby Sterilin Ltd, Stone, UK) to convey isolates to the central laboratory, proved to be highly successful, with an overall recovery rate of 95%.
1,2 Microdilution MICs were determined for isolates for penicillin, amoxicillin, amoxicillin/clavulanic acid, cefaclor, cefuroxime, cefixime, ceftriaxone, erythromycin, clarithromycin, azithromycin, doxycycline, chloramphenicol, ciprofloxacin, ofloxacin and trimethoprim/ sulfamethoxazole (co-trimoxazole).
1,2 These antimicrobials were included for the full 10 years of the study, and were chosen by the project Steering Committee based on therapeutic relevance, availability, local prescribing habits and the desire to address specific issues of interest. 1 Over the course of the study, additional antimicrobials were added. These included ampicillin (added in 1994), cefotaxime and loracarbef (tested only in 1998), grepafloxacin and trovafloxacin (tested from 1998 to 2000), cefprozil, cefdinir, clindamycin, levofloxacin and gemifloxacin (added in 1998), and gatifloxacin and moxifloxacin (added in 2000). These compounds were included either to reflect new agents introduced into clinical use or for elucidation of resistance mechanisms, as in the case of clindamycin for testing S. pneumoniae, and ampicillin, which was added to allow for appropriate testing of H. influenzae and detection of b-lactamase-negative, ampicillin-resistant (BLNAR) strains. MICs for isolates were determined using microbroth dilution. 1 For isolates of H. influenzae and S. pneumoniae, MuellerHinton broth (Accumen International Ltd, East Grinstead, UK), supplemented with saponin-lysed horse blood and Factor V, was initially used. 1 After 1997, Haemophilus test medium (HTM) was used for the testing of H. influenzae, with the quality of HTM carefully checked before each lot was used, and cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood was used for testing S. pneumoniae. Susceptibility to the above antimicrobials was determined based on MIC values and using breakpoints published by the NCCLS. Breakpoints used to assess susceptibility in the project were updated in line with amendments made to the NCCLS published breakpoints over the years of the study. However, once data had been analysed in the project, it became clear that, particularly with some of the cephalosporins when tested against S. pneumoniae, reporting only MIC 50 , MIC 90 and per cent susceptibility failed to provide adequate information and was not able to detect the early emergence of more resistant isolates. 1 Therefore, in the project, complete MIC frequency distribution tables were published, allowing assessment of the comparative potency of the antimicrobials tested, as well as re-analysis in light of changes in interpretative criteria. 1 Quality control with regard to the identification of pathogens included identifying isolates once at the collecting laboratory and again at the regional central laboratory. The following six control strains were initially used as quality control for the determination of MICs: S. aureus NCTC 6571, Escherichia coli NCTC 10418, Pseudomonas aeruginosa NCTC 10662, H. influenzae NCTC 11931, H. influenzae ATCC 49247 and S. pneumoniae ATCC 49619.
1 Later Alexander Project protocol amendments specified the following control strains be used: H. influenzae ATCC 49247 and ATCC 49766, S. pneumoniae ATCC 49619, E. coli ATCC 25922 and ATCC 35218, and S. aureus ATCC 29213. In addition, H. influenzae ATCC 10211 was to be used as a control organism for quality-control testing of HTM. The standardized methods used, ii4
and the MIC distributions obtained in the project (which followed patterns previously identified for the organisms studied), confirm the high quality of the data obtained in the study. 3 Furthermore, the use of a panel of reference isolates with known susceptibility and resistance ensured that participating laboratories were producing high-quality results. An additional, indirect quality-assurance measure was the comparison of several agents. By comparing values obtained in the project with known relationships that exist between the MIC values of various agents, the quality of the data could be evaluated. 3 Further, MIC distributions were analysed to confirm that modal MIC values for the agents tested were as expected. As modal MICs for drug-pathogen combinations with unimodal, bimodal or multimodal distributions do not tend to change over time, this was a useful means of assessing the quality of the data. The intentional quality-control measures employed, and the quality-assurance checks provided by comparisons of data, ensured that the Alexander Project was a source of valid and reliable surveillance data. 3 In 1996, the Alexander Project expanded to include centres in Mexico and Brazil (Latin America), Saudi Arabia (Middle East), South Africa (Africa) and Hong Kong (Far East), as well as the addition of centres in 10 European countries not previously included ( Figure 1) . 4 An additional six countries from a number of continents joined in 1998, further reducing any possible geographical bias in the prevalence of resistance reported that may have resulted from the earlier limited distribution of centres ( Figure 1 ). 5 
Management of the Alexander Project
The Alexander Project was supported for its duration solely by a grant from GlaxoSmithKline or its predecessor SmithKlineBeecham. The project protocol, methodologies and decisions with respect to interpretation and dissemination of data were managed by an Alexander Project Steering Committee comprising independent experts (Appendix 1). The key investigators (Appendix 2) also contributed suggestions regarding antimicrobials to be tested and areas of interest to be studied.
Benefits of the Alexander Project
Although the primary aim of the Alexander Project was to establish a database of antimicrobial susceptibility and to observe changes over time, the isolates collected and the data generated have proved to be a key resource in the understanding of the nature and causes of antibacterial resistance in respiratory tract pathogens (Figure 2 ). Areas that have benefited from the use of project data and isolates include comparative differentiation between agents and classes, the application of pharmacokinetic/pharmacodynamic (PK/PD) parameters and subsequent use of PK/PD-derived breakpoints, correlations between antimicrobial usage and resistance trends over time, and studies on the evolution and mechanisms of resistance.
The wide range of antimicrobials tested in the Alexander Project and the use of MIC values for assessment enabled differentiation between individual agents and classes of antimicrobials that was not possible using only the qualitative susceptible, intermediate and resistant interpretations generally available from other surveillance studies at the time of the start of the project. 1 Results of the project demonstrated a difference in the potency of oral agents against S. pneumoniae, both within and across classes, and the impact of resistance mechanisms. 6, 7 For example, the activity, based on MIC 90 , of amoxicillin was greater when compared with the activity of oral cephalosporins, penicillin and ampicillin. 6 Goldstein and Acar 6 suggested that the intrinsic activity and pharmacodynamics of some b-lactams result in these agents being potentially more effective than penicillin G and consequently suitable for use against some penicillin-resistant pathogens. Goldstein and Acar's 6 analysis of project isolates also demonstrated co-resistance to penicillin and non-b-lactam agents, particularly co-trimoxazole and macrolides.
The relevance of the range of MICs within the bacterial population also raised the question of the potential microbiological or clinical significance of elevated MICs to each individual agent. For example, Grüneberg 7 found discrepancies between susceptibility rates, based on NCCLS breakpoints current at the time, and the intrinsic activity of antibacterials suggested by MIC distributions when testing the susceptibility of S. pneumoniae to b-lactams and that of H. influenzae to macrolides. Consequently, further analyses were conducted, including the determination of modal MIC and MIC 90 Alexander Project: a decade of surveillance ii5 classes (C max :MIC 90 ratio), amoxicillin/clavulanic acid was found to have the greatest activity against the key respiratory tract pathogens. 7 However, it is now accepted that there is no single parameter that can act as the most accurate measure for all antimicrobial classes. Different characteristics of the various antimicrobial classes, such as concentration-dependent versus time-dependent activity and post-antibiotic effects, determine which PD parameter is most suited to predicting the activity of an agent. It should be noted that the antibacterial activity of amoxicillin/clavulanic acid is based on its amoxicillin content, with the clavulanic acid component protecting the amoxicillin from inactivation by b-lactamase. MIC distribution data from the project, together with additional supporting PK/PD, animal efficacy and clinical data, led to the adoption in 1995 by the NCCLS of specific susceptibility breakpoints for amoxicillin and amoxicillin/clavulanic acid against S. pneumoniae, which differed from the previous interpretation of only penicillin G-susceptible isolates being susceptible to these agents. 8 The PK properties of amoxicillin differ from those of penicillin G, and thus isolates may be penicillin-resistant but remain susceptible to amoxicillin. 9 Several criteria have been suggested for determining whether or not a surveillance study provides data useful in the clinical setting. Among these are timeliness, accuracy, consistent and standardized methods of collection and analysis-including the use of a central laboratory and internationally accepted standard procedures, the collection of appropriate demographic data, ongoing chronological data collection (year-on-year), quality-control measures and reporting on major pathogens found in community-acquired or nosocomial infections. [10] [11] [12] [13] [14] Additionally, high-quality surveillance programmes should be able to identify significant differences, as well as changes and trends, in susceptibility to the agents tested. 15 The Alexander Project met these criteria and provided global and regional reference data on emerging trends likely to influence broad prescribing practices. Data were collected annually over the 10 years of the study and were reported regularly through conference abstracts, symposia proceedings and journal articles. A search Methods of collection and analysis established at the beginning of the project were generally employed throughout the duration of the study. Where changes were made, these were supported by rigorous checks and correlations to ensure consistency and accuracy of results. Although the original central laboratory expanded to three regional sites, strenuous quality-control measures and stringent quality assurance was introduced to ensure comparability of testing results. 3 Although the project excluded isolates from nosocomial infections, it reported extensively and consistently on the three most common pathogens found in communityacquired bacterial respiratory infections.
The benefits offered by the Alexander Project continue through the ongoing use of the isolate collection. The entire European collection and 7 years of the USA, Latin America and Asia collections have been placed in the public domain and are available from the HPA (formerly the Central Public Health Laboratory), Colindale, London, UK.
Towards a better understanding of resistance
The Alexander Project data and emerging resistance trends generated a great deal of interest in the factors driving antimicrobial resistance. For example, Baquero 16 examined the correlation between the use of oral cephalosporins relative to aminopenicillins and increases in the prevalence of penicillin resistance in S. pneumoniae in France. It was postulated that failure of most oral cephalosporins to eradicate the infecting pathogen due to inadequate time above MIC (t > MIC) had greatly contributed to the development and spread of pneumococcal resistance. 16 Data from the project were later used by Baquero 17 to study the correlation between the quantity of particular agents used and the increased prevalence of resistance among isolates of S. pneumoniae. In this subsequent study, Baquero 17 found that there was an increase in pneumococcal macrolide resistance in countries where the long-acting macrolides clarithromycin and azithromycin had been introduced and had come into common and widespread use. This may be due to the long half-life of these drugs prolonging pathogen exposure to subinhibitory concentrations of these agents. 17 Analysis of surveillance data, together with information on antimicrobial use (such as that undertaken by Baquero), is useful in helping to understand the complexity of resistance development.
14 Similar studies and correlations have subsequently been undertaken in individual countries using national surveillance data. 18, 19 This remains an important area of resistance research, particularly as new agents become available and in countries in which antimicrobials are sold 'over the counter '. Analysing the data-the application of PK/PD data to breakpoints
The PK properties of a drug are its absorption, distribution and elimination within the body, whereas the PD properties are the pharmacology and toxicology of a drug. 20 The relationship between PK and PD determines the overall efficacy potential of a particular dosage regimen and can help to define optimal 
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antimicrobial therapy for organisms of differing antibacterial susceptibilities. 20, 21 In the late 1980s, Craig and co-workers, among others, investigated the interrelationship between PK, PD and antibacterial efficacy in animal models. 22, 23 Craig and Ebert 24 showed that the standard in vitro measures of MIC and MBC did not fully predict antimicrobial activity in vivo, as these measures do not take into account PK/PD effects. Further work in animal models and accumulated evidence from clinical studies in various indications suggested that PK/PD parameters could be used to predict antimicrobial bacteriological efficacy. 23, [25] [26] [27] [28] For b-lactams, bacterial killing is time-dependent. The t > MIC as a percentage of the dosing interval that non-protein-bound serum drug concentrations are above MIC values is indicative of bacteriological activity. 29 Using project isolates, Drusano and Goldstein 30 evaluated the t > MIC 50 and t > MIC 90 achieved with various drug-pathogen combinations to determine which exceeded the minimum 50% of the dosing interval, the parameter thought to be required at that time. This was the first time that such a PK/PD 'breakpoint' was assessed, and results of additional research based on clinical data in acute otitis media were soon published that supported these findings. 31 Based on their results, Drusano and Goldstein 30 recommended that, in addition to in vitro activity, PK/PD characteristics, determined in part by site of infection and toxicity profile, be taken into account in antimicrobial selection. As research into PK/PD parameters continued using both animal models and clinical studies, it was found that for some b-lactams, such as amoxicillin, a t > MIC of 35-40% of the dosing interval was predictive of high rates of bacterial eradication. [31] [32] [33] Using standard dosing regimens and serum pharmacokinetics, it is possible to determine the unbound serum drug concentrations that are maintained for the minimum required t > MIC for a particular antimicrobial with time-dependent activity, and this provides the PK/PD-based breakpoint. 34 For fluoroquinolones, such as ciprofloxacin, levofloxacin, moxifloxacin and the newer agent, gemifloxacin, and aminoglycosides bacterial killing is concentration-dependent, and the area-under-the-curve to MIC ratio (AUC:MIC) or peak concentration, again based on non-protein-bound serum concentrations to MIC ratio (C max :MIC) determines bacteriological activity. 28, 29 As clinical cure correlates with an AUC:MIC ratio exceeding 25-30, PK/PD-based breakpoints for these agents can be determined by using the formula AUC/25. 34 Importantly, these MIC ratios are based on free-drug concentrations, and protein binding of fluoroquinolones can vary considerably across the class, from 30 to 70%.
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Early research into the PK/PD activity of the macrolides suggested that erythromycin should be evaluated based on t > MIC, azithromycin based on the AUC:MIC ratio and clarithromycin based on either of these parameters. 30 Recently, however, Craig and co-workers have suggested that the free-drug AUC:MIC ratio may more accurately predict bacterial killing by both macrolides and azalides. 28 Other studies support the use of t > MIC as a predictor of efficacy for erythromycin. 36 However, azithromycin is known to have prolonged and persistent post-antibiotic effects, making concentration-dependent measures better predictors of clinical efficacy for this drug. 37 Once PK/PD parameters for bacteriological efficacy were understood, it became clear that a method of accurately comparing the activity of different antibiotics was needed that took these parameters into account and therefore compared potential clinical efficacy. 30 Grüneberg and co-workers, 38 using project data, analysed PK/PD-based breakpoints compared with NCCLS breakpoints current at the time and found that although the two sets of breakpoints were generally in agreement, the NCCLS breakpoints seemed to underestimate the susceptibility of S. pneumoniae to amoxicillin/clavulanate and ceftriaxone. Consequently, susceptibility breakpoints derived from PK/PD criteria were proposed in 1997-98 by Grüneberg, and by Craig and co-workers. [38] [39] [40] Similarly, increasing understanding of PK/PD parameters highlighted discrepancies between certain published susceptibility breakpoints, for example, those of oral cephalosporins, and concentrations that were clinically achievable. 41 In contrast to the cephalosporins, however, Goldstein showed that a clinically achievable dose of amoxicillin would be effective against many penicillin-resistant S. pneumoniae, demonstrating that in addition to MICs, an awareness of PK/PD properties is needed to choose an optimal oral b-lactam. 42 Goldstein 42 also found discrepancies between the NCCLS breakpoints at that time and PK/PD breakpoints for the b-lactams, proposing upper resistance breakpoints for several of the oral b-lactams.
In January 2000, the NCCLS published new susceptibility breakpoints, based on in vitro microbiology, PK/PD data, and animal and clinical efficacy data, for the oral b-lactams amoxicillin with or without clavulanic acid (£2 mg/L, based on amoxicillin
Subsequently, a study by Jacobs et al. 44 used PK/PD-based breakpoints 45 (Table 2 ) to determine the in vitro susceptibility of respiratory pathogens to a range of antimicrobials. Using PK/ PD-based breakpoints, amoxicillin/clavulanate was shown to be active against >90% of S. pneumoniae and H. influenzae isolates, whereas susceptibility of S. pneumoniae to cefaclor and loracarbef was <25%, and that of H. influenzae to these agents was <10%. Using PK/PD-based breakpoints, virtually no H. influenzae isolates were susceptible to the macrolides tested. 44 PK/PD breakpoints offer a valuable means of evaluating antibacterial activity, as they do not vary by pathogen in the case of the key respiratory organisms (S. pneumoniae, H. influenzae and M. catarrhalis). 20, 21 Furthermore, they are based on in vivo animal efficacy and, in the case of S. pneumoniae and H. influenzae, clinical data, particularly in acute otitis media, where bacteriological efficacy was determined.
46 Double tympanocentesis studies in otitis media, in which tympanocentesis is performed before the start of therapy and repeated after 4-6 days of therapy, allow the direct measurement of in vivo bacteriological activity of antibacterials and have added to the demonstration and validation of PK/PD-derived parameters and breakpoints. 32 Clinical studies such as these confirmed that PK/PD parameters accurately predict bacteriological eradication in the clinical setting. 47 Although the NCCLS breakpoints for S. pneumoniae for certain antimicrobials have been modified and are now in line with PK/PD breakpoints, NCCLS breakpoints provide no interpretative criteria for M. catarrhalis, and substantial discrepancies remain between the NCCLS and PK/PD breakpoints for H. influenzae (Table 2) . 48, 49 Identifying mechanisms of resistance
The Alexander Project isolate collection has allowed focused studies on specific organisms with defined resistances occurring Alexander Project: a decade of surveillance ii7 at low prevalences as well as examples of common resistance phenotypes. For example, examining isolates of H. influenzae collected between 1997 and 2000 in the project, Peric et al. 50 were able to identify a macrolide efflux mechanism in the majority (>98%) of isolates with baseline macrolide MICs that are classified as susceptible by NCCLS criteria. In strains that had azithromycin MICs > 4 mg/L, ribosomal mutations were also seen, conferring 'high-level' resistance at a prevalence of 1.3%. 50 Thus, the unimodal distribution of H. influenzae MIC values seen among isolates from the project in 2001 (0.06-64 mg/L) reflects an intrinsic macrolide efflux mechanism in the vast majority of isolates, and most have MICs greater than the PK/PD-derived susceptible breakpoints.
In other analyses of Alexander Project isolates, non-b-lactamase mechanisms of resistance have been suggested in both H. influenzae (BLNAR) and M. catarrhalis with elevated amoxicillin MICs. 51, 52 Although extremely rare elsewhere, BLNAR isolates are common in Japan, with a prevalence of 30%, and are of concern because they express resistance to penicillins, cephalosporins and carbapenems. 53, 54 Rare isolates of b-lactamase-positive, amoxicillin/ clavulanate-resistant H. influenzae from the project, all isolated in Japan, have also been found, and have altered penicillinbinding-protein 3 (the mechanism of resistance in BLNAR strains), as well as TEM-1 b-lactamase as mechanisms of resistance. 54 Project data have also been used to analyse the mechanisms of macrolide resistance and quinolone resistance in isolates of S. pneumoniae, as well as to explore the mechanisms of activity of the fluoroquinolones against H. influenzae. 55, 56 For example, the global collection of isolates held by the project has provided a means to track the emergence and spread of resistant clones among isolates of S. pneumoniae. Using isolates from the project, it was possible to identify resistant clones in Northern Ireland and France as belonging to the Spain 9V -3 clone, and a further four quinolone-resistant strains that were closely related to or identical with the Spain 23F -1 clone. 57 Results from a recently published phenotypic analysis of macrolide-resistant S. pneumoniae isolates collected over the 10 years of the project in France, Spain and Italy indicate that resistance mechanisms in these isolates are evolving towards an increased prevalence of 'poorly regulated inducible' erm(B)-mediated resistance, which results in higher MICs of the macrolides. 57 Additionally, this study found that 8.0% of macrolide-resistant isolates did not display a known resistance mechanism. 56 It is probably that these isolates possess one or more ribosomal mutations. 58, 59 Poupard et al. 60 used data from the Alexander Project to explore new data-mining strategies as a means of analysing the results of surveillance studies. They were able to evaluate the variability and diversity between isolates of a species, the number of isolates susceptible to all antimicrobials tested and track the origins of changes in susceptibility to individual countries.
60,61
Key results of the Alexander Project
The Alexander Project was the first surveillance study to identify long-term trends in antimicrobial resistance of communityacquired respiratory tract infection pathogens. Six countries were part of the study from 1992 (France, Germany, Italy, Spain, the UK and the USA) and 10 years of data are now available. Five years of data have been collected for seven of the countries that joined in 1996. Susceptibility and resistance to individual antimicrobials are based on 2004 NCCLS breakpoints.
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S. pneumoniae
For all six countries participating in the project since 1992, the prevalence of penicillin resistance in S. pneumoniae (penicillin MICs ‡ 2 mg/L) increased between 1992 and 2001, with the greatest increases seen in France (1992, 7.7%; 2001, 35 .8%) and the USA (1992, 5.6%; 2001, 20 .4%) ( Figure 3 ). In Europe, there was an overall average increase in penicillin resistance among S. pneumoniae of 8.1% over this 10 year period. 63 For these six countries, the rate of erythromycin resistance (erythromycin MICs ‡ 1 mg/L) exceeded that of penicillin resistance in S. pneumoniae both at the start of the study and in 2001 in all countries except Spain. The greatest difference was in Italy (erythromycin resistance, 35.9%; penicillin resistance, 4.9% in 2001). Huff et al. 63 calculated the risk ratio for an increase in the prevalence of erythromycin resistance versus the risk ratio for an increase in the prevalence of penicillin resistance for each of these countries over the 10 years. The odds of an increase were 2.43 times greater for erythromycin resistance than for penicillin resistance in the five European countries combined, and 1.22 times greater in the USA. 63 Using data from the project, Mera et al. 64, 65 determined that, in the USA and Europe, the annual increase in the prevalence of multidrug-resistant S. pneumoniae was 3%, exceeding the annual increase in the prevalence of single-drug-resistant S. pneumoniae. The ability to analyse trends over a 10 year time period increases the ability of such data to demonstrate 'true' rates of change.
In addition to trends over time, Alexander Project data from the USA have identified differences between regions in the prevalence of penicillin and macrolide resistance among S. pneumoniae. Jacobs and co-workers 34 found that only one of the regions studied (northwest USA) had a prevalence of penicillin resistance <20%, and that this difference between the northwest and other regions was significant (P < 0.005). Additionally, the northwest was found to have a significantly lower prevalence of macrolide resistance than other regions (P < 0.05). 34 Three of the six original participating countries experienced a dramatic increase in the prevalence of penicillin-erythromycin co-resistance in S. pneumoniae. In 2001, France had the highest prevalence of penicillin-erythromycin co-resistance (32.7% of all S. pneumoniae) followed by Spain (17.0% of all S. pneumoniae) and the USA (15.3% of all S. pneumoniae). In 1992, the prevalence of penicillin-erythromycin co-resistance for these same countries was 1.8, 3.7 and 3.2% of total S. pneumoniae, respectively. The prevalence of penicillin-resistant S. pneumoniae that were erythromycin-susceptible and erythromycin-resistant in these three countries is shown in Figure 4 . Over the 10 years of the project, the prevalence of S. pneumoniae isolates co-resistant to penicillin, erythromycin and co-trimoxazole has been increasing in the USA and, in 2001, 71.4% of penicillin-resistant S. pneumoniae were also resistant to erythromycin and co-trimoxazole. 64 Ofloxacin resistance, used as a marker of fluoroquinolone resistance, among isolates of S. pneumoniae remained at a low prevalence in France (1.2%), Germany (0.7%), Spain (0.9%) and the USA (0.7%) in 2001.
In addition to assessing susceptibility and resistance based on NCCLS breakpoints, PK/PD-based breakpoints have been used in the Alexander Project. The susceptibility, based on PK/PD-derived breakpoints, of S. pneumoniae to nine antimicrobials that were tested throughout the 10 years of the study in the six original participating countries, and for which PK/PD breakpoints exist, is provided in Table 3 .
Among the seven countries joining the Alexander Project in 1996 and providing isolates in each year from 1996 to 2001, Hong Kong, Saudi Arabia and Mexico had a prevalence of penicillin resistance among S. pneumoniae exceeding 10% in 1996 and 2001 ( Figure 5 ). The greatest changes in penicillin resistance between 1996 and 2001 were seen in South Africa (increased from 3.6 to 12.1%) and Switzerland (increased from 3.2 to 9.4%) ( Figure 5 ).
The prevalence of erythromycin resistance in S. pneumoniae exceeded that of penicillin resistance in 1996 in all of these countries except Saudi Arabia, and in all seven countries in 2001. In 2001, the prevalence of erythromycin resistance was >10% in all countries except Poland ( Figure 5 ).
Among these seven countries, ofloxacin resistance among S. pneumoniae was highest in Hong Kong (18.4%) in 2001, although also seen in Belgium (0.5%). Co-resistance to penicillin and erythromycin was highly prevalent among ofloxacin-resistant S. pneumoniae in Hong Kong, with 93.8% of these strains isolated in 2001 resistant to penicillin and 100% resistant to erythromycin. As the Spain 9V -3 and Spain 23F -1 clones are predominantly responsible for the presence of quinolone-resistant and multidrug-resistant S. pneumoniae in many countries, 57 it was thought that these clones might also be responsible for the high prevalence of quinolone resistance seen in Hong Kong, and for the emergence of quinolone resistance in other countries. Recent research by Morrissey et al. 66 has confirmed that the quinolone-resistant strains of S. pneumoniae identified in Hong Kong belong to the Spain 23F -1 clone.
H. influenzae
For the six countries participating in the Alexander Project since 1992, b-lactamase production in H. influenzae increased in the UK (1992, 6.8%; 2001, 15.4%) and France (1992, 16.1%; 2001, 35 .6%) ( Figure 6 ). Although decreasing in the other four countries over this period, b-lactamase production in H. influenzae remained as high as 24.5% in the USA in 2001. As with penicillin and macrolide resistance among S. pneumoniae, one region of the USA, in this case the southwest, was found to have a significantly (P < 0.05) lower prevalence of b-lactamase production among H. influenzae than other regions studied. 34 In these six countries, 100% of H. influenzae isolates were susceptible to azithromycin in 1992, and susceptibility to azithromycin remained >99.0% in 2001, using the NCCLS breakpoint. Using the PK/PD-based breakpoint of £0.12 mg/L, however, susceptibility was <2.0% in five of the six countries in both years. In the UK, 2.9% of isolates collected in 2001 were susceptible at this breakpoint. There was no appreciable decrease in the percentage of H. influenzae susceptible to ofloxacin in 1992 and in 2001 in any of the six countries. The percentage of H. influenzae susceptible to co-trimoxazole decreased in 2001, compared with 1992, in all of these countries except France, with the greatest decreases in susceptibility rates noted in Germany (1992, 89.8%; 2001, 67.7%) and the USA (1992, 97.4%; 2001, 77.7%) .
As there are no NCCLS breakpoints for doxycycline against H. influenzae, the PK/PD-based breakpoint of 0.25 mg/L was used to assess susceptibility. The percentage of H. influenzae susceptible to doxycycline decreased in 2001, compared with 1992, in all six countries (Table 4) .
Among the seven countries that joined the Alexander Project and provided isolates from 1996 to 2001, Hong Kong, Saudi Arabia and Belgium all had a prevalence of b-lactamase production in H. influenzae >20% in the first year of contributing to the study ( Figure 7 ). Among these three countries, only Saudi Arabia had an increase in the prevalence of b-lactamase production in 2001 compared with 1996.
There were no H. influenzae isolates collected in Mexico in 1996. In the remaining six countries that joined the Alexander Project in that year, there was no decrease in the percentage of H. influenzae susceptible to azithromycin and ofloxacin, using NCCLS breakpoints, in 2001 compared with 1996. Using the PK/PD-based breakpoint of £0.12 mg/L, however, <1.0% of H. influenzae from any of these six countries were susceptible to azithromycin. H. influenzae susceptibility to co-trimoxazole decreased in all six countries in 2001, compared with 1996, with the greatest decreases in Saudi Arabia (1992, 70.9%; 2001, 34.6%) and South Africa (1992, 87.7%; 2001, 49.5%) . H. influenzae susceptibility to doxycycline, based on the PK/PD breakpoint, decreased in all six countries in 2001, compared with 1996 (Table 4) .
M. catarrhalis
In 2001, M. catarrhalis was collected in France, Germany, the UK, Poland and Hong Kong. In France, the UK and Hong Kong, 100% of M. catarrhalis isolates were b-lactamase-positive, as were 88.9 and 90.9% of isolates from Germany and Poland, respectively. Generally, b-lactamase production must now be considered a defining characteristic of clinical isolates of this species. In France, Hong Kong and Poland, 100% of M. catarrhalis isolates were susceptible to ofloxacin and co-trimoxazole. There were too few 1993 1994 1995 1996 1997 1998 1999 2000 2001 n = 13 n = 49 n = 72 n = 118 n = 53 n = 53 n = 45 n = 77 n = 58 n = 59 n = 67 n = 76 n = 97 n = 113 n = 31 n = 61 n = 23 n = 34 n = 21 n = 32 n = 7 n = 9 n = 16 n = 10 n = 13 n = 23 n = 132 n = 248 n = 229 n = 112 Table 3 . Percentage of S. pneumoniae isolates that were susceptible to nine antimicrobials a included in the six countries in the Alexander Project since 1992 at PK/PD breakpoints over 10 years Country/drug  1992  1993  1994  1995  1996  1997  1998  1999  2000  2001 France n = 169 n = 225 n = 189 n = 284 n = 165 n = 181 n = 126 n = 173 n = 145 isolates collected in Germany and the UK to make a valid assessment of susceptibility.
The continuing importance of surveillance
Since the inception of the Alexander Project, other international surveillance studies have been initiated, most notably SENTRY, MYSTIC, PROTEKT, LIBRA, TRUST and TSN (Appendix 4). Each of these studies is helpful in adding to the overall body of susceptibility data, and has both strengths and limitations. SENTRY, which was initiated in 1997, is an international study covering four geographic regions: North America, South America, Europe and Asia-Pacific. 67, 68 The MYSTIC surveillance study focuses on seven antimicrobials, and has 3 years of data currently available on isolates collected from hospital centres that are active users of meropenem. Pathogens known to be resistant to meropenem are excluded. 69 The PROTEKT study is a global study, with over 200 participating laboratories in the USA and a further 90 centres worldwide testing 14 antimicrobials against major respiratory pathogens. 70, 71 The LIBRA study has existed since 1997 and collects susceptibility data for respiratory and urinary pathogens for 28 antimicrobials worldwide. 72 The TRUST study is a USA-based longitudinal surveillance study, begun in 1996, focusing on bacterial respiratory pathogens. 73 TSN collects data from >200 hospital-based laboratories in the USA, as well as networks in Australia, Canada, France, Germany and Italy, and evaluates the susceptibility of a variety of pathogens, including the key respiratory pathogens, to commonly used antimicrobials. [74] [75] [76] [77] As pioneered by the Alexander Project, SENTRY, MYSTIC, PROTEKT, LIBRA and TRUST all make use of central laboratory systems. 68, 70, 72, 78, 79 For the MYSTIC study, however, the central laboratory system does not appear to be utilized in all geographic 11.5 (18/156) 8.3 (12/144) 3.7 (1/27) 20 80 Also similar to the Alexander Project is the focus on community-acquired respiratory isolates of S. pneumoniae, H. influenzae and M. catarrhalis in the SENTRY and PROTEKT studies. 68, 70 The SENTRY, MYSTIC and LIBRA studies followed the lead of the Alexander Project by publishing MIC frequency distributions and summary tables, rather than just qualitative susceptible, intermediate and resistant figures. 16, 72 In addition to industry-funded surveillance programmes, government-sponsored surveillance studies also exist. One example of this is EARSS, 81 founded in 1998 with the aim of harmonizing antibiotic resistance surveillance in Europe. The system is funded by the European Commission and the Dutch Ministry of Health, Welfare and Sports, and is coordinated by the National Institute of Public Health and the Environment of The Netherlands.
Currently, 28 countries participate in EARSS, involving over 600 laboratories.
EARSS is targeted at monitoring resistance to a limited number of antibiotics among five invasive bacterial species, including S. pneumoniae. One advantage of EARSS is that there is no perception of commercial influence. EARSS has been successful in gathering valuable resistance data from across the continent. In addition, the large number of laboratories helps to ensure that data is representative of the Europe-wide picture. However, there are limitations associated with EARSS, primarily that it is restricted to invasive isolates and the limited number of antibacterials tested. Additionally, susceptibility testing is not centralized and is performed at a large number of laboratories employing varied techniques. 82 This is in contrast to industry-funded programmes, which as discussed above, often use a central testing laboratory allowing susceptibility screening to be standardized according to internationally recognized quantitative techniques.
Isolates collected as part of surveillance studies can also be used to test the in vitro activity of new agents for development and registration purposes. Isolates in the Alexander Project were used to test the new quinolone, gemifloxacin, and to assess the activity of the new high-dose ratios of amoxicillin/clavulanate using PK/PD breakpoints. 83, 84 Both MYSTIC and PROTEKT include newly developed agents in their studies to determine activity against clinical isolates of common pathogens (meropenem and telithromycin, respectively). Although all surveillance studies have limitations, there are benefits to be gained through having a variety of studies with different, overlapping objectives. The wealth of year-on-year data being collected indicates the value of good quality longitudinal surveillance as pioneered by the Alexander Project.
The challenge of increasing resistance
As the prevalence of resistance to commonly used antimicrobials continues to increase, and as resistance becomes established in countries or regions where pathogens were previously susceptible, there will be increased pressure on the choice of appropriate antibiotics. Additionally, the prevalence of resistance to multiple drugs, particularly among isolates of S. pneumoniae, is increasing in many areas. This further limits the agents that can be used for empirical prescribing.
Facing the challenge of resistance
The increasing prevalence of antimicrobial resistance, particularly multidrug resistance, seen in isolates of S. pneumoniae, H. influenzae and M. catarrhalis in the Alexander Project, demonstrates a need for new strategies to combat this problem. Studies using project data indicate the complex relationship between antibacterial prescribing and resistance. However, over the period of the study, evidence has emerged confirming the importance of bacterial eradication in respiratory tract infection. 32, 85, 86 Bacterial eradication not only maximizes clinical success, but also minimizes the potential for selecting and maintaining resistant strains. 32, 85 Thus, in terms of quality in prescribing, where antibacterial therapy is indicated, the optimal agent will need to be capable of eradicating strains of the relevant bacterial pathogens, particularly strains resistant to other agents, as well as having a good safety/tolerability profile. In terms of the quantity of prescribing, policies that guard against either over-prescribing or Alexander Project: a decade of surveillance ii13 under-prescribing may be required. 86 Organizations such as the CDC and the WHO support the use of educational campaigns to improve levels of appropriate prescribing. 87, 88 As most prescribing for respiratory tract infections will continue to be empirical, a key element in appropriate prescribing is knowledge of which pathogens are common in the local area and the likelihood of encountering resistant strains. Thus, local resistance data should be taken into account in the choice of antimicrobial. To this end, surveillance studies can indicate countries in which the overall prevalence of resistance is high, and regions where physicians should regularly be made aware of this problem in their area. 85 Furthermore, surveillance in countries with a low prevalence of resistance, such as the Russian Federation, can detect early changes in resistance patterns and trends. Additionally, agents with appropriate coverage and PK/ PD properties should be available and used to maximize bacterial eradication. 85 Data from studies such as the Alexander Project have contributed to the research and development of antibacterials designed to overcome resistance to established agents. 89 The increased understanding of the relationship between PK/PD and antibacterial activity afforded by studies of isolates collected as part of surveillance programmes has allowed PK/PD-based formulations of existing agents to be developed, such as pharmacokinetically enhanced amoxicillin/clavulanate, which was designed to combat S. pneumoniae with elevated penicillin and amoxicillin MICs in regions where these strains are emerging. 90 The Alexander Project: conclusions Over the 10 years since its inception, the Alexander Project has led the way in international, longitudinal surveillance of antimicrobial resistance. The use of standardized methods and a system of central laboratories has allowed the comparison of data from several centres, across countries, and globally. It has also provided valuable data on the trends in prevalence of antimicrobial resistance within countries and regions. As data from the project cover several years, it has been possible to compare trends in the evolution of resistance with antimicrobial consumption and to analyse the correlation between use and resistance. Although the project had only one or two centres in most participating countries, and this may not be representative of the country as a whole (particularly in large countries, such as the Russian Federation), it allows unique tracking over time of the prevalence of resistance for each centre. Isolates collected in the project have also been valuable in assessing the mechanisms leading to antimicrobial resistance, particularly blactam and macrolide resistance in S. pneumoniae and H. influenzae. Application of PK/PD parameters to the analysis of MIC distributions led to the assessment of isolate susceptibility using PK/PD-based breakpoints.
The Alexander Project was established to create a large database of longitudinal information on the prevalence of resistance in the common community-acquired respiratory pathogens, and to disseminate that data in a useful manner. In addition to the data that have been published from the project, an isolate collection from the study has been put into the public domain to facilitate future research. This is the first global surveillance study to make its isolates formally available for public use. More than 80 publications and presentations based on data from the project demonstrating trends in the development and spread of resistance, and the many other areas of research that have been undertaken, show that the Alexander Project was, indeed, a highly successful undertaking.
Furthermore, the collection of 10 years of isolates and data held by the project provide a unique source for ongoing studies on mechanisms of resistance, pathogen evolution and retrospective comparisons of resistance and possible factors driving the emergence and spread of resistance.
In 2002, the Alexander Project was superseded by the Alexander Network. The Alexander Network, like the Alexander Project before it, continues to provide an integrated source of quality data and interpretations from surveillance studies around the globe. It also explores further the relationships between antimicrobial resistance and prescribing patterns. In addition, data from the Alexander Network, which includes 11 individual studies, have been made publicly available through the Alexander Network web site (www.alexandernetwork.com) . 91 This web site contains both educational material and tools for conducting data analyses.
Although the costs of running a long-term, global surveillance study, such as the Alexander Project, are high, it is anticipated that shorter-term global, regional and local surveillance studies will continue to play a key role in the fight against antimicrobial resistance, helping to further extend our understanding of resistance development and its relationship with appropriate prescribing.
